NASDAQ$ATEC

Alphatec Holdings Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Total revenue increased by 27%, driven by 30% growth in surgical revenue, and adjusted EBITDA margin expanded by 450 basis points.

Alphatec Holdings, Inc. reported strong first-quarter 2024 financial results, with total revenue growing 27% to $138 million and surgical revenue increasing by 30%. The company also raised its full-year revenue and adjusted EBITDA guidance to $601 million and $23 million, respectively.

  • Surgical revenue grew 30% with a 23% increase in surgical volume and a 6% increase in average revenue per procedure.
  • Hosted 150 surgeon training engagements, fueling a 21% growth in surgeon adoption and increasing utilization.
  • Continued to elevate U.S. footprint with expansion in several major markets and 28% growth in established territories.
  • Deployed approximately $60 million of revenue-generating assets to capitalize on market opportunity.

Headline financials

Total Revenue

$138M

Previous: $109M+26.9%
EPS

-$0.34

Previous: -$0.40+15.0%
Adjusted EBITDA

-$3.04M

No prior period
Adjusted EBITDA Margin

-2.2%

Previous: 1080.0%-100.2%
Capital Expenditures

-$31.3M

Previous: -$16.3M-92.4%
Free Cash Flow

-$79.8M

Previous: -$59.8M-33.4%
Net Income

-$48.5M

Previous: -$43.5M-11.4%
Operating Income

-$43.3M

Previous: -$40.3M-7.4%
Gross Profit

$97.4M

Previous: $70.4M+38.2%
Cash & Equivalents

$144M

Previous: $117M+23.5%
Total Assets

$775M

Previous: $570M+36.0%
R&D Expense

$18M

No prior period
Stock-Based Comp

$17.3M

Previous: $16.5M+5.2%

Revenue & EPS history

Alphatec · Revenue · Quarterly

$138M

Q1 2024+26.9%vs Q1 2023
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

Alphatec · $104M total across 1 segment · Q3 2023

  • Surgical Revenue
    $104M

Forward guidance

For the full year 2024, the Company now expects total revenue to grow 25% to $601 million, including surgical revenue of $536 million and EOS revenue of $65 million. The Company also expects non-GAAP adjusted EBITDA of approximately $23 million.

Tailwinds

  • Total revenue expected to grow 25% to $601 million.
  • Surgical revenue expected to be $536 million.
  • EOS revenue expected to be $65 million.
  • Non-GAAP adjusted EBITDA expected to be approximately $23 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-1.5%

Avg return

Earnings day

-1.4%

Avg return

5 days after

-0.1%

Avg return

30 days after

45%

29 / 64 earnings

Positive

+44.8%

Q3 2024

Best reaction

-43.2%

Q2 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.9%-27.1%-23.3%
Q4 2025+0.5%-3.3%-21.5%
Q3 2025-0.8%+17.8%+36.7%
Q1 2025+2.4%+2.2%+2.2%
Q4 2024+9.6%+6.1%-7.9%
Q3 2024+44.8%+54.2%+93.4%
Q2 2024-32.8%-33.7%-30.2%
Q1 2024-20.2%-13.3%-22.7%
Q4 2023-7.4%-11.1%-8.6%
Q3 2023+4.7%-1.5%+20.8%
Q2 2023-7.1%-10.4%-5.2%
Q1 2023+3.1%+3.8%+4.5%
Q4 2022+1.6%+7.9%+6.3%
Q3 2022-1.5%-1.4%+9.5%
Q2 2022-0.2%-3.8%-10.9%
Q1 2022-16.1%-27.7%-34.0%
Q4 2021+3.1%+3.4%+4.4%
Q3 2021-2.2%-8.2%-18.7%
Q2 2021+2.4%-5.8%-0.2%
Q1 2021-2.0%-9.1%-8.3%
Q4 2020-7.6%+4.2%-2.1%
Q3 2020+9.4%+4.7%+22.1%
Q2 2020+21.8%+5.6%+3.1%
Q1 2020-8.0%-13.9%+5.7%
Q4 2019-8.4%-20.8%-47.2%
Q3 2019+15.2%+16.1%+18.1%
Q2 2019+9.3%+8.5%+26.2%
Q1 2019+5.4%+15.8%+8.8%
Q4 2018+14.7%+16.6%+22.1%
Q3 2018-1.7%-5.6%-13.5%
Q2 2018+4.7%+15.0%+28.1%
Q1 2018-2.0%-0.9%-1.1%
Q4 2017+0.9%-5.0%+1.2%
Q3 2017-0.8%-0.6%-30.5%
Q2 2017+2.4%+2.4%+40.2%
Q1 2017+1.9%+0.0%-4.8%
Q4 2016-16.0%-27.0%-45.8%
Q3 2016-15.8%-8.0%-12.8%
Q2 2016+2.5%+0.0%-6.5%
Q1 2016-11.8%
Q4 2015-13.8%
Q3 2015+5.8%
Q2 2015-42.6%
Q1 2015+1.4%
Q4 2014+7.4%
Q3 2014-0.7%
Q2 2014+0.0%
Q1 2014+2.3%
Q4 2013+22.3%
Q3 2013-0.5%
Q2 2013-3.9%
Q1 2013-3.2%
Q4 2012+2.6%
Q3 2012-1.8%
Q2 2012-2.5%
Q1 2012-7.4%
Q4 2011-0.5%
Q3 2011-5.6%
Q2 2011-10.4%
Q1 2011+3.7%
Q4 2010+0.4%
Q3 2010-9.6%
Q2 2010-43.2%
Q1 2010+6.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro